full comment requir non-u analyst conflict disclosur
pleas click link
op metric improv high leverag matur profil remain concern
omidubicel pivot progress attent expand program
posit id
turnaround continu drive tangibl result
lower estim destock softer volum maintain op
nt factor cap outlook brand momentum lt algo tact
 of daili summari
find research
insight www rbcinsightresearch com global research destin web contact capit market sale
repres access global research site
miss cost headwind guidanc re-affirmed low end
struggl continu
charg
focu pc gpu
expect due time guidanc target reiter
price prior day market close estimate unless otherwis note
valu usd unless otherwis note
valu cad unless otherwis note
op metric improv high leverag matur profil remain
follow-up first glanc note publish provid addit
commentari recent result compani outlook also lower
estim reduc price target add specul risk qualif
rate given uncertainti regard turnaround leverag
ration program draw close soon
on-going servic line capac invest cost-reduct initi
driven solid improv volum trend mix margin remain
howev leverag remain high lower ebitda outlook certainli
doesnt help trajectori term return sustain leverag
rang enterpris
exchang offer could help matur profil somewhat signific risk
recent move equiti follow wednesday correct seem
adequ reflect state enterpris hard see much upsid
absent declin leverag progress matur
nt factor cap outlook brand momentum lt algo tact
despit strong top line qoq shift tough compar hong kong
weak near-term lead deceler impli reiter fy
sale outlook like room outlook note timing/
extern factor play remain buyer acknowledg investor need
regain comfort goo lt top line outlook despit near-term headwind
maintain ep pt
goo stock perform volatil year
recalibr expect year posit revis
maintain top/bottom line outlook suggest goo growth
stori along said look next year expect
goo busi approach vs noth
call indic underli brand heat momentum chang
beyond qoq time shift extern factor certainli result demonstr
gooss brand strength momentum across channel geographi
see wholesal pull-forward shipment
pressur wholesal revenu guid mid-teen street
reiter annual hsd wholesal outlook suggest msd
ldd model sale growth wholesale/direct
direct
valu usd unless otherwis note
channel dynam like impress ebit margin
expect invest market off-set gain updat
ep emb gm gain overal margin
return expans
tweak estim lower price target ep includ
pt move appli
ep averag net incom
forward guid came well expect mid-point revenu
growth vs consensu quarterli result solid ahead
consensu guidanc stori slightli lower pt
moder growth expect still view best
posit network name event increasingli challeng macro
disappoint guidanc drive convers expect jan-qtr
revenu growth surpris declin compar our/consensu
guid ep vs our/consensu
gross margin guidanc outpac our/consensu
consensu bottom bracket
slight posit near-term revenu outlook like domin
convers headlin share after-hour
write manag note uncertainti impact busi confid
point issu surround hong kong latam us-china trade brexit
signific overhang
make today result go forward posit thesi
initi best posit potenti challeng
macro favor posit viewpoint compar peer remain
growth non-exist year believ like across board
-specif issu still believ well posit
benefit near-term industri cycl longer-
term outlook gener unchang
silver line gross margin report guidanc came
expect suggest adequ adjust
expect software-driven gross margin improv servic provid
weak less bad sequenti order vs last qtr
admittedli neither enough off-set enterprise/commerci order
omidubicel pivot progress attent expand
sound program execut draw gmda closer string key pipelin event
catalyst pivotal-stag cell-expand
omidubicel on-track import readout early-stag nk asset
pois program watch given foundat earli matur
valu usd unless otherwis note
valu usd unless otherwis note
data larger clinic plan continu see emerg
interest set-up capabl drive new pipelin attent share appreci
tweak pt updat reiter
omidubicel remain track enrol target complet
set import top-line would anticip clariti
data specif time content venu later time parallel
manag maintain focu file commerci activ
steadi sequenc bla file includ eu effort potenti
launch intact
on-going explor product clinic mechanist profil
import input omidubicel ultim market attract look
new moa data nam-bas cell expans flesh
gmda platform see note core driver valuat
prospect peak sale ww omidubicel enter critic phase
sever proof point provid greater clariti around potenti
remain earli though updat continu gener increas
attent still direct encourag set-up larger nhl studi
expect cut addit patient longer durat oral
support pathway forward nhl addit new investig
context around learn mm cohort net-net expect
data compani pre-work underway sensibl plan design
new trial trigger greater clariti next step help program
step forward viabl valu creat asset behind omidubicel
lower estim destock softer volum maintain op
remain optimist despit destock headwind
continu see strong accept lt contract stabl contract price
allow strong capit return market
af report adj ebitda our/street
ep our/street estim due lower
ebitda total revenu y/i
declin impact lower sale volum higher raw materi cost
relat parti petroleum needl coke sale volum sold came
ton project wtd average price
estim oper rate
total lower price target base
ebitda prior rais ev/ebitda multipl
potenti trough-lik condit revisit estim
multipl destock complet volum increas
observ broader recoveri steel market
maintain outperform maintain rate base stabl contract
price averag like well spot strong expect
capit return market cap least annual
